Table 2 Current treatment, relapsing, disease status, death, neoplasia, and follow-up of patients with dermatomyositis
From: The relevance of anti-Jo-1 autoantibodies in patients with definite dermatomyositis
Anti-Jo-1 (+) (n = 10) | Anti-Jo-1 (−) (n = 108) | P value | |
|---|---|---|---|
Treatment | |||
Prednisone | |||
Current use | 7 (70.0) | 32 (29.6) | 0.015 |
Current dose (mg/day) | 15 [5–40] | 10 [5–40] | 0.788 |
Immunosuppressive drugs | 10 (100.0) | 63 (58.3) | 0.013 |
Methotrexate | 3 (30.0) | 27 (25.0) | 0.715 |
Azathioprine | 1 (10.0) | 22 (20.4) | 0.684 |
Mycophenolate mofetil | 5 (50.0) | 14 (13.0) | 0.010 |
Cyclosporine | 1 (10.0) | 6 (5.6) | 0.471 |
Leflunomide | 1 (10.0) | 7 (6.5) | 0.519 |
Intravenous immunoglobulin | 1 (10.0) | 1 (0.9) | 0.163 |
Rituximab | 2 (20.0) | 11 (10.2) | 0.307 |
Disease relapse | 7 (70.0) | 56 (51.9) | 0.508 |
Current disease status | |||
Disease remission | 0 | 38 (35.2) | – |
Complete clinical response | 2 (20.0) | 32 (29.6) | 0.722 |
Disease activity | 0 | 10 (9.3) | – |
Death | 1 (10.0) | 9 (8.3) | > 0.999 |
Neoplasia | 0 | 0 | – |
Follow-up | 10 (100.0) | 58 (53.7) | 0.005 |